High Growth Tech Stocks in Australia Featuring Infomedia and Two Others

The Australian market has shown resilience, with the ASX200 rising by 1.35% to 8,325 points amid positive global economic signals such as a slowdown in U.S. consumer prices and robust earnings from major American banks. As all sectors remain in positive territory, particularly Real Estate and Financials leading the gains, investors are keenly observing how these dynamics might influence high-growth tech stocks like Infomedia and others, which thrive on innovation and adaptability in such evolving conditions.

Top 10 High Growth Tech Companies In Australia

Name	Revenue Growth	Earnings Growth	Growth Rating
Infomedia	6.77%	20.97%	★★★★★☆
Clinuvel Pharmaceuticals	21.38%	26.16%	★★★★★☆
Pureprofile	14.31%	71.53%	★★★★★☆
Adherium	86.80%	73.66%	★★★★★★
Pro Medicus	20.41%	22.03%	★★★★★★
AVA Risk Group	25.54%	77.32%	★★★★★★
Mesoblast	49.13%	54.30%	★★★★★★
Wrkr	37.21%	98.46%	★★★★★★
Opthea	54.54%	60.67%	★★★★★★
SiteMinder	18.83%	60.68%	★★★★★☆

Click here to see the full list of 58 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Infomedia (ASX:IFM)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Infomedia Ltd is a technology company that develops and supplies electronic parts catalogues, service quoting software, and e-commerce solutions for the automotive industry worldwide, with a market cap of A$524.66 million.

Operations: Infomedia generates revenue primarily through its publishing of periodicals, amounting to A$140.83 million. The company focuses on providing electronic parts catalogues and service quoting software tailored for the automotive industry globally.

Infomedia, a player in the Australian tech scene, is actively pursuing mergers and acquisitions to bolster long-term shareholder value, as highlighted by CEO Jens Monsees' recent statement. While its annual revenue growth at 6.8% is modest compared to the broader Australian market's 5.9%, earnings are on a robust trajectory with an expected annual increase of 21%. This outpaces the national average significantly. The company's R&D commitment remains strong, crucial for sustaining its competitive edge in software innovation. Additionally, Infomedia's earnings surged by 32.4% over the past year, surpassing industry growth and indicating effective operational execution despite facing a significant one-off financial setback of A$8.6 million last June.

• Get an in-depth perspective on Infomedia's performance by reading our health report here.

• Explore historical data to track Infomedia's performance over time in our Past section.

Pro Medicus (ASX:PME)

Simply Wall St Growth Rating: ★★★★★★

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system (RIS) software to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$26.51 billion.

Operations: The company generates revenue primarily through the production of integrated software applications for the healthcare industry, amounting to A$161.50 million.

Pro Medicus stands out in the Australian tech landscape, demonstrating robust growth with its revenue and earnings expanding at annual rates of 20.4% and 22.03%, respectively, significantly outpacing the broader market's growth. This performance is underpinned by strategic initiatives such as presenting at key industry events like the Bell Potter Healthcare Conference, signaling ongoing engagement with the investment community and potential investors. Notably, its commitment to innovation is reflected in substantial R&D investments that drive its competitive edge in healthcare technology solutions. With a projected Return on Equity of an impressive 49.6% within three years and a positive free cash flow status, Pro Medicus appears well-positioned to sustain its growth trajectory while adapting to dynamic market demands.

• Take a closer look at Pro Medicus' potential here in our health report.

• Understand Pro Medicus' track record by examining our Past report.

SiteMinder (ASX:SDR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: SiteMinder Limited develops, markets, and sells online guest acquisition platforms and commerce solutions for accommodation providers in Australia and internationally, with a market cap of A$1.61 billion.

Operations: SiteMinder generates revenue primarily through its software and programming segment, amounting to A$190.84 million. The company's focus on providing online guest acquisition platforms and commerce solutions caters to accommodation providers both in Australia and internationally.

SiteMinder, a notable entity in Australia's tech arena, is navigating the competitive landscape with promising financial indicators. The company's revenue is projected to ascend by 18.8% annually, outpacing the broader Australian market's growth of 5.9%. This upward trajectory is complemented by an anticipated surge in earnings, expected to grow at a remarkable rate of 60.7% per year. Investing significantly in innovation, SiteMinder allocated substantial funds towards R&D, reinforcing its commitment to advancing technology solutions within the hospitality sector. These strategic investments not only bolster its market position but also enhance its service offerings to high-profile clients globally, setting the stage for sustained growth and potential industry leadership.

• Navigate through the intricacies of SiteMinder with our comprehensive health report here.

• Gain insights into SiteMinder's past trends and performance with our Past report.

Next Steps

• Unlock our comprehensive list of 58 ASX High Growth Tech and AI Stocks by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com